Vaccine triggers immune response, prevents Alzheimer's

Vaccinated mice generated an immune response to the protein known as amyloid-beta peptide, which accumulates in what are called “amyloid plaques” in brains of people with Alzheimer’s. The vaccinated mice demonstrated normal learning skills and functioning memory in spite of being genetically designed to develop an aggressive form of the disease.

The Rochester scientists reported the findings in an article in the May issue of Molecular Therapy, the journal of The American Society of Gene Therapy.

“Our study demonstrates that we can create a potent but safe version of a vaccine that utilizes the strategy of immune response shaping to prevent Alzheimer’s-related pathologies and memory deficits,” said William Bowers, associate professor of neurology and of microbiology and immunology at the Medical Center and lead author of the article. “The vaccinated mice not only performed better, we found no evidence of signature amyloid plaque in their brains.”

Alzheimer’s is a progressive neurodegenerative disease associated with dementia and a decline in performance of normal activities. Hallmarks of the disease include the accumulation of amyloid plaques in the brains of patients and the loss of normal functioning tau, a protein that stabilizes the transport networks in neurons. Abnormal tau function eventually leads to another classic hallmark of Alzheimer’s, neurofibrillary tangle in nerve cells. After several decades of exposure to these insults, neurons ultimately succumb and die, leading to progressively damaged learning and memory centers in the brain.

The mice that received the vaccines were genetically engineered to express large amounts of amyloid beta protein. They also harbored a mutation that causes the tau-related tangle pathology. Prior to the start of the vaccine study, the mice were trained to navigate a maze using spatial clues. They were then tested periodically during the 10-month study on the amount of time and distance traveled to an escape pod and the number of errors made along the way.

“What we found exciting was that by targeting one pathology of Alzheimer’s — amyloid beta — we were able to also prevent the transition of tau from its normal form to a form found in the disease state,” Bowers said.

The goal of the vaccine is to prompt the immune system to recognize amyloid beta protein and remove it. To create the vaccine, Bowers and the research group use a herpes virus that is stripped of the viral genes that can cause disease or harm. They then load the virus container with the genetic code for amyloid beta and interleukin-4, a protein that stimulates immune responses involving type 2 T helper cells, which are lymphocytes that play an important role in the immune system.

The research group tested several versions of a vaccine. Mice were given three injections of empty virus alone, a vaccine carrying only the amyloid beta genetic code, or a vaccine encoding both amyloid beta and interlueikin-4, which was found to be the most effective.

“We have learned a great deal from this ongoing project,” Bowers said. “Importantly, it has demonstrated the combined strengths of the gene delivery platform and the immune shaping concept for the creation of customized vaccines for Alzheimer’s disease, as well as a number of other diseases. We are currently working on strategies we believe can make the vaccine even safer.”

Bowers expects the vaccine eventually to be tested in people, but due to the number of studies required to satisfy regulatory requirements, it could be three or more years before human trials testing this type of Alzheimer’s vaccine occur.

Source: University of Rochester Medical Center

Potatoes may hold key to Alzheimer's treatment
A virus that commonly infects potatoes bears a striking resemblance to one of the key proteins implicated in Alzheimer's disease (AD), and researchers have used that to develop antibodies that may slow or prevent the onset of AD.
Can tomatoes carry the cure for Alzheimer's?
The humble tomato could be a suitable carrier for an oral vaccine against Alzheimer's disease, according to HyunSoon Kim from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Korea and colleagues from Digital Biotech Inc. and the Department of Biological Science at Wonkwang University.
Paving the way toward a vaccine against Alzheimer's disease
Scientists have provided new details about how proteins used to destroy bacteria and viruses may help treat Alzheimer’s disease. Gunnar K. Gouras, associate professor of neurology and neuroscience at Weill Medical College of Cornell University, New York, and colleagues provide new insights into how these proteins, called antibodies, reduce the main hallmarks of Alzheimer’s disease and raise hopes for a vaccine against the disease.
Brain inflammation may be friend, not foe, for Alzheimer's patients
Inflammation in the brain may not be so bad after all when it comes to Alzheimer’s disease.In the June 1 issue of the Journal of Clinical Investigation, a team of scientists from the University of Rochester Medical Center shows that a key inflammatory regulator, a known villain when it comes to parsing out damage after a stroke and other brain injuries, seems to do the opposite in Alzheimer’s disease, protecting the brain and helping get rid of clumps of material known as plaques that are a hallmark of the disease.
Immune antibodies penetrate neurons to clear Alzheimer's-linked amyloid
Researchers at Weill Cornell Medical College have gotten much closer to understanding how immune-based therapies can treat Alzheimer's disease -- by studying how antibodies go inside brain cells to reduce levels of Alzheimer's-linked amyloid peptides that form plaques between neurons.
Scientists develop a new way to target Alzheimer's disease
The pathological embrace between two proteins plays a key role in the development of Alzheimer's disease by triggering the formation of neuron-killing plaques of amyloid beta protein. Now a group of scientists at NYU School of Medicine have devised a way to reduce amyloid beta deposition by interfering with the deadly embrace of these proteins.
New results, trial for Alzheimer's vaccine
Training the body's immune system to fight back against Alzheimer's disease may still offer a promising option for slowing or even preventing the tragic brain disorder that affects 4.5 million Americans.
RNA molecules boost vaccine effectiveness
(PhysOrg.com) -- A novel delivery system that could lead to more efficient and more disease-specific vaccines against infectious diseases has been developed by biomedical engineers at The University of Texas at Austin.

Vaccine triggers immune response, prevents Alzheimer's

Related stories:

News discussion: